23.10.2023 17:15:33 - dpa-AFX: AZN : Enhertu Shows Survival Across Multiple HER2-Expressing Advanced Solid Tumors In Phase II Trial
LONDON (dpa-AFX) - Positive results from the primary analysis of the ongoing
DESTINY-PanTumor02 Phase II trial showed that Enhertu (fam-trastuzumab
deruxtecan-nxki) continued to demonstrate clinically meaningful and durable
responses, leading to a clinically meaningful survival benefit in previously
treated patients across multiple HER2-expressing advanced solid tumors,
AstraZeneca (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) said in a statement.
Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC)
being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
The companies noted that Enhertu showed a median progression-free survival of
6.9 months and median overall survival of 13.4 months in the overall trial
population.
According to the companies, the results reaffirm potential role of Enhertu as a
tumor-agnostic therapy for previously treated patients with HER2-expressing
solid tumors and support ongoing discussions with global regulatory authorities.
For More Such Health News, visit rttnews.com
Copyright(c) 2023 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
![](/mel/img/quote_button.gif) |
DAIICHI SANKYO CO. LTD |
A0F57T |
Frankfurt |
36,740 |
31.07.24 08:29:43 |
+2,500 |
+7,30% |
37,210 |
38,320 |
36,740 |
34,240 |
![](/mel/img/quote_button.gif) |
ASTRAZENECA PLC DL-,25 |
886455 |
Xetra |
146,400 |
31.07.24 14:42:48 |
+1,100 |
+0,76% |
146,100 |
146,300 |
145,350 |
145,300 |